Related Experiment Video
Updated: Jul 8, 2026

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay
Published on: October 4, 2024
STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes
Pavel Krejci1, Lisa Salazar, Helen S Goodridge
1Institute of Experimental Biology, Masaryk University, 61137 Brno, Czech Republic. krejcip@scimuni.cz
Abstract:
Activating mutations in fibroblast growth factor receptor 3 (FGFR3) cause several human skeletal dysplasias as a result of attenuation of cartilage growth. It is believed that FGFR3 inhibits chondrocyte proliferation via activation of signal transducers and activators of transcription (STAT) proteins, although the exact mechanism of both STAT activation and STAT-mediated inhibition of chondrocyte growth is unclear. We show that FGFR3 interacts with STAT1 in cells and is capable of activating phosphorylation of STAT1 in a kinase assay, thus potentially serving as a STAT1 kinase in chondrocytes. However, as demonstrated by western blotting with phosphorylation-specific antibodies, imaging of STAT nuclear translocation, STAT transcription factor assays and STAT luciferase reporter assays, FGF does not activate STAT1 or STAT3 in RCS chondrocytes, which nevertheless respond to a FGF stimulus with potent growth arrest. Moreover, addition of active STAT1 and STAT3 to the FGF signal, by means of cytokine treatment, SRC-mediated STAT activation or expression of constitutively active STAT mutants does not sensitize RCS chondrocytes to FGF-mediated growth arrest. Since FGF-mediated growth arrest is rescued by siRNA-mediated downregulation of the MAP kinase ERK1/2 but not STAT1 or STAT3, our data support a model whereby the ERK arm but not STAT arm of FGF signaling in chondrocytes accounts for the growth arrest phenotype.
Insights
Activating fibroblast growth factor receptor 3 (FGFR3) mutations cause skeletal issues. Research shows FGFR3-induced chondrocyte growth arrest relies on ERK signaling, not STAT proteins, clarifying this mechanism in skeletal dysplasias.
Area of Science:
- Cell Biology
- Skeletal Biology
- Molecular Biology
Background:
- Activating mutations in fibroblast growth factor receptor 3 (FGFR3) lead to skeletal dysplasias by impairing cartilage growth.
- FGFR3 is thought to inhibit chondrocyte proliferation through signal transducers and activators of transcription (STAT) proteins, but the precise mechanism is unknown.
Purpose of the Study:
- To investigate the role of STAT proteins in FGFR3-mediated chondrocyte growth arrest.
- To determine whether the ERK pathway or STAT pathway mediates FGF-induced growth arrest in chondrocytes.
Main Methods:
- Kinase assays to assess FGFR3's potential as a STAT1 kinase.
- Western blotting, STAT nuclear translocation imaging, transcription factor assays, and luciferase reporter assays to evaluate STAT activation.
- RNA interference (siRNA) to downregulate ERK1/2, STAT1, and STAT3 to assess their role in FGF-mediated growth arrest.
Main Results:
- FGFR3 interacts with and can phosphorylate STAT1 in vitro, but FGF does not activate STAT1 or STAT3 in chondrocytes.
- Activating STAT1 or STAT3 did not sensitize chondrocytes to FGF-induced growth arrest.
- FGF-mediated growth arrest was rescued by downregulating ERK1/2, but not STAT1 or STAT3.
Conclusions:
- The ERK signaling pathway, not STAT signaling, mediates FGF-induced growth arrest in chondrocytes.
- This finding clarifies the molecular mechanism underlying FGFR3-associated skeletal dysplasias.
Related Concept Videos
TGF - β Signaling Pathway
The JAK-STAT Signaling Pathway
Activation and Inactivation of G Proteins
Hedgehog Signaling Pathway
Negative Regulator Molecules

